OTCMKTS:BICX BioCorRx (BICX) Stock Price, News & Analysis $0.41 +0.06 (+17.86%) As of 03/28/2025 03:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsSEC FilingsShort InterestBuy This Stock About BioCorRx Stock (OTCMKTS:BICX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioCorRx alerts:Sign Up Key Stats Today's Range$0.37▼$0.4150-Day Range$0.26▼$1.0052-Week Range$0.26▼$1.50Volume21,208 shsAverage Volume14,262 shsMarket Capitalization$6.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.Read More… Remove Ads BioCorRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreBICX MarketRank™: BioCorRx scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for BioCorRx. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCorRx is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCorRx is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioCorRx's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.06% of the float of BioCorRx has been sold short.Short Interest Ratio / Days to CoverBioCorRx has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioCorRx has recently increased by 222.73%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioCorRx does not currently pay a dividend.Dividend GrowthBioCorRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.06% of the float of BioCorRx has been sold short.Short Interest Ratio / Days to CoverBioCorRx has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioCorRx has recently increased by 222.73%, indicating that investor sentiment is decreasing significantly. News and Social Media1.0 / 5News SentimentN/A News SentimentBioCorRx has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BioCorRx this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioCorRx insiders have not sold or bought any company stock.Percentage Held by Insiders21.40% of the stock of BioCorRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about BioCorRx's insider trading history. Receive BICX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCorRx and its competitors with MarketBeat's FREE daily newsletter. Email Address BICX Stock News HeadlinesBioCorRx (OTCMKTS:BICX) Share Price Passes Below 200-Day Moving Average - Time to Sell?March 21, 2025 | americanbankingnews.comBioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLCMarch 10, 2025 | finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.March 29, 2025 | Paradigm Press (Ad)La Rosa Holdings Corp. secures new financing, reshuffles leadershipOctober 6, 2024 | investing.comBioCorRx Inc: BioCorRx Reports Business Update for the Second Quarter of 2024August 16, 2024 | finanznachrichten.deBioCorRx Reports Business Update for the Second Quarter of 2024August 15, 2024 | globenewswire.comBioCorRx Reports Business Update for the First Quarter of 2024May 16, 2024 | finance.yahoo.comBioCorRx Inc. (BICX)April 18, 2024 | finance.yahoo.comSee More Headlines BICX Stock Analysis - Frequently Asked Questions How have BICX shares performed this year? BioCorRx's stock was trading at $0.38 at the beginning of 2025. Since then, BICX stock has increased by 8.6% and is now trading at $0.4125. View the best growth stocks for 2025 here. How were BioCorRx's earnings last quarter? BioCorRx Inc. (OTCMKTS:BICX) released its quarterly earnings data on Thursday, November, 17th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm earned $0.17 million during the quarter. How do I buy shares of BioCorRx? Shares of BICX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioCorRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCorRx investors own include PlayAGS (AGS), Ashford Hospitality Trust (AHT), Peabody Energy (BTU), Mondi (MNDI), Assertio (ASRT), Astronics (ATRO) and CONSOL Coal Resources (CCR). Company Calendar Last Earnings11/17/2016Today3/29/2025Next Earnings (Estimated)3/31/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Specialty outpatient clinics, not elsewhere classified Sub-IndustryHealthcare Current SymbolOTCMKTS:BICX CIK1443863 Webwww.biocorrx.com Phone(714) 462-4880FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,770,000.00 Net Margins-11,600.00% Pretax Margin-18,340.74% Return on EquityN/A Return on Assets-1,074.47% Debt Debt-to-Equity RatioN/A Current Ratio0.04 Quick Ratio0.04 Sales & Book Value Annual Sales$90,000.00 Price / Sales73.08 Cash FlowN/A Price / Cash FlowN/A Book Value($1.14) per share Price / Book-0.36Miscellaneous Outstanding Shares15,945,000Free Float11,920,000Market Cap$6.58 million OptionableNot Optionable Beta0.57 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (OTCMKTS:BICX) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCorRx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCorRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.